2,706
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Clinical and molecular characteristics of acute myeloid leukemia with MPL mutation

, , , , & ORCID Icon

References

  • Mignotte V, Vigon I, de Crèvecoeur EB, et al. Structure and transcription of the human c-mpl gene (MPL). Genomics. 1994;20(1):5–12.
  • Jacob G, Jyoti N, Joanna B E, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379(15):1416–1430.
  • Fox NE, Chen R, Hitchcock I, et al. Compound heterozygous c-Mpl mutations in a child with congenital amegakaryocytic thrombocytopenia: functional characterization and a review of the literature. Exp Hematol. 2009;37(4):495–503.
  • Deutsch VR, Tomer A. Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside. Br J Haematol. 2013;161(6):778–793.
  • Huan L, Na Z, Yihui L, et al. c-MPL Is a candidate surface marker and confers self-renewal, quiescence, chemotherapy resistance, and leukemia initiation potential in leukemia stem cells. Stem Cells. 2018;9999:1–12.
  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
  • Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: An open platform for exploring multidimensional Cancer Genomics data. Cancer Discov. 2012;2(5):401–404.
  • Germeshausen M, Ballmaier M. CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations- heterogeneity of a monogenic disorder - comprehensive analysis of 56 patients. Haematologica. 2021;106(9):2439–2448.
  • Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112(1):141–149.
  • Beer PA, Ortmann CA, Stegelmann F, et al. Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica. 2010;95(12).
  • Wang X, Haylock D, Hu CS, et al. A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells. Blood. 2016;127(26):3398–3409.
  • Cui L, Moraga I, Lerbs T, et al. Tuning MPL signaling to influence hematopoietic stem cell differentiation and inhibit essential thrombocythemia progenitors. Proc Natl Acad Sci. 2021;118(2):e2017849118.